FDA accepts Intellia's IND for CRISPR and TCR-T cell therapy; Santé closes Fund IV at $260M
Riding the coattails of a massive $600 million cash raise in June, Intellia announced that the FDA accepted their IND …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
